$DNA

Coen Steven P. sold $3K of DNA

Coen Steven P. (See remarks) sold 307 shares of Ginkgo Bioworks Holdings, Inc. (DNA) at $8.33 on 2026-05-22.

Original reporting
SEC EDGAR · Coen Steven P.
Published May 26, 2026, 9:04 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 26, 2026, 9:07 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$DNA
Neutral
low confidence
Mentioned
$DNA
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DNANeutralLow
01

Why it matters

This provides a datapoint on insider behavior but does not include operational, financial, or regulatory developments for the company.

02

Market read

Traders may briefly adjust sentiment on DNA based on insider selling, but the disclosed transaction is small and not a standalone fundamental catalyst.

03

What to watch

No 10b5-1 plan is cited, but the filing also lacks intent/valuation context; track whether multiple insiders sell around the same time.

Relevance 6/10Timing: Immediate awareness for sentiment/positioning; not a catalyst by itself.

Background

The filing is an SEC Form 4 insider transaction disclosure for Ginkgo Bioworks Holdings, Inc.

Company-level read

Ticker impact

$DNANeutralLow confidence
Context

Ginkgo Bioworks officer Coen Steven sold 307 shares in an open-market transaction, disclosing direct holdings and sale price on SEC Form 4.

Expected impact

Likely limited immediate impact; any reaction should fade unless follow-on selling or broader negative catalysts emerge.

Evidence & confidence

This is a routine Form 4 insider transaction without company-specific operational news; size (~$2.6K) is small relative to typical market moves and no 10b5-1 plan is stated.

Market effects

Minimal; single-company Form 4 selling rarely resets biotech/biomanufacturing risk appetite.

None indicated.

None indicated.

Counterpoint

The sale may be for diversification, taxes, or personal liquidity rather than a negative view on fundamentals.

Key entities

  • Ginkgo Bioworks Holdings, Inc.

    Subject of the Form 4 insider sale by officer Coen Steven P.

  • Coen Steven P.

    Officer who executed an open-market sale of 307 shares at $8.3340 on 2026-05-22.

Related articles

$DNAMed

Ginkgo Bioworks Q2 Earnings Call Highlights

Ginkgo Bioworks (NYSE:DNA) reported first-half 2026 cash burn of $93M, down 3% from $96M a year earlier. Management said Q1 cash burn included a $14M Google Cloud payment tied to an amended 2025 commitment that cut future minimums by over $100M and extended the term to six years. Ginkgo expanded its Nebula lab to 105 racks and raised $17M via an ATM.

$DNAMed

Ginkgo Bioworks Holdings, Inc. (DNA): Results of Operations and Financial Condition

Ginkgo Bioworks Holdings, Inc. (DNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991earningspr.htm EX-99.1 Document Exhibit 99.1 Ginkgo Bioworks Reports Second Quarter 2026 Results, Wins Government Contracts to Build Autonomous Labs at MIT, Caltech, Northwestern, and University of Maryland Ginkgo provides an update on its second quarter financial

$DNAMed

Researchers are building AI-powered robot labs. What does this mean for science?

NPR reports that Ginkgo Bioworks in Boston is developing an “autonomous lab” where AI directs robots to run experiments, including drug discovery, fertilizer microbes, and protein design. Founders say AI is moving from automating tasks to generating hypotheses, including an OpenAI collaboration using GPT‑5 to design a cell-free protein synthesis reaction. Stanford’s Drew Endy warns of biosecurity and skills-loss risks.

$DNAMed

Researchers are building AI-powered robot labs. What does this mean for science?

NPR reports that researchers at Ginkgo Bioworks in Boston are building “autonomous labs” where AI and robots handle tasks such as pipetting, scheduling experiments, and even generating hypotheses. Founders Jason Kelly and Reshma Shetty say AI is being used to design experiments overnight and to collaborate with OpenAI on cell-free protein synthesis. Stanford’s Drew Endy warns about biosecurity and loss of scientific know-how.